BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Leukine (Sargramostim) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Leukine (Sargramostim)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04902703-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT04902703)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: Phase II Trial to Eva
 luate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease\nE
 stimated primary completion: 30 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04902703
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01757626-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leukine (Sargramostim): Phase 1/2 readout est. (NCT01757626)
DESCRIPTION:Leukine (Sargramostim)\, phase 1/2.\nStudy: Combination Therapy
  of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor 
 (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT01757626
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04211675-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leukine (Sargramostim): Phase 1/2 readout est. (NCT04211675)
DESCRIPTION:Leukine (Sargramostim)\, phase 1/2.\nStudy: NK Cells Infusions 
 With Irinotecan\, Temozolomide\, and Dinutuximab\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04211675
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04237623-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT04237623)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: GM-CSF With Post-Tran
 splant Cyclophosphamide\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04237623
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078604-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT07078604)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: A Cancer Vaccine (STE
 MVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative
  Metastatic Triple-Negative Breast Cancer\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sargram
 ostim#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07078604
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04936529-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT04936529)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: A Study of a Vaccine 
 in Combination With β-glucan and GM-CSF in People With Neuroblastoma\nEst
 imated primary completion: 15 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04936529
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02502786-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT02502786)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: Humanized Monoclonal 
 Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor
  (GM-CSF) in the Treatment of Recurrent Osteosarcoma\nEstimated primary co
 mpletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02502786
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027748-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT07027748)
DESCRIPTION:Leukine (Sargramostim)\, phase 1.\nStudy: Feasibility Study of 
 Prolonged Administration of Naxitamab\, Irinotecan\, and Temozolomide for 
 Patients With Relapsed or Refractory Neuroblastoma\nEstimated primary comp
 letion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07027748
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514898-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT06514898)
DESCRIPTION:Leukine (Sargramostim)\, phase 1.\nStudy: Adoptive T Cell Thera
 py\, DC Vaccines\, and Hematopoietic Stem Cells Combined With Immune check
 POINT Blockade in Patients With Medulloblastoma\nEstimated primary complet
 ion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06514898
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374029-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT07374029)
DESCRIPTION:Leukine (Sargramostim)\, phase 1\, Acute Myeloid Leukemia.\nStu
 dy: Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and
  Venetoclax in AML\nEstimated primary completion: 1 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07374029
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254326-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT06254326)
DESCRIPTION:Leukine (Sargramostim)\, phase 1.\nStudy: ADAGiO: Adoptive Cell
 ular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult P
 atients\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06254326
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202066-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT06202066)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: Temozolomide and Surv
 ivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Pro
 gressing Metastatic Neuroendocrine Carcinomas\nEstimated primary completio
 n: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06202066
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05544968-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT05544968)
DESCRIPTION:Leukine (Sargramostim)\, phase 1.\nStudy: Anti-CD30 biAb-AATC i
 n Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignanci
 es\nEstimated primary completion: January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05544968
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085338-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT07085338)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: A Phase II Study With
  a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone
  for the Treatment of Patients With Relapsed or Refractory Neuroblastoma\n
 Estimated primary completion: 1 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07085338
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377435-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT07377435)
DESCRIPTION:Leukine (Sargramostim)\, phase 1.\nStudy: DC/MM Fusion Vaccine 
 With BCMA CAR-T in R/R MM\nEstimated primary completion: 1 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07377435
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Leukine (Sargramostim): Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Leukine (Sargramostim)\, phase 1/2.\nStudy: Personalized Neoant
 igen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment
  of Advanced Solid Tumors\nEstimated primary completion: 31 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05269381
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03630211-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT03630211)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: Autologous Stem Cell 
 Transplantation in Patients With Systemic Sclerosis\nEstimated primary com
 pletion: 1 August 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03630211
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799026-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Leukine (Sargramostim): Phase 1 readout est. (NCT06799026)
DESCRIPTION:Leukine (Sargramostim)\, phase 1.\nStudy: A Phase 1 Study of Va
 ccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combin
 ation With Elranatamab in Relapsed or Refractory Multiple Myeloma\nEstimat
 ed primary completion: 1 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06799026
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06450041-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT06450041)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: NANT 2021-01 Phase II
  STING (Sequential Temozolomide\, Irinotecan\, NK Cells and GD2 mAb) Trial
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06450041
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169617-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT07169617)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: Testing the SurVaxM V
 accine for Lung Cancer Prevention\nEstimated primary completion: 30 March 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sargramostim#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071696
 17
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528496-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20290722
DTEND;VALUE=DATE:20290723
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT06528496)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: N10: A Study of Reduc
 ed Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children Wi
 th Neuroblastoma\nEstimated primary completion: 22 July 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06528496
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07437963-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Leukine (Sargramostim): Phase 1/2 readout est. (NCT07437963)
DESCRIPTION:Leukine (Sargramostim)\, phase 1/2.\nStudy: Testing the Additio
 n of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back
 \, Not Responded to Treatment\, or Gotten Worse\nEstimated primary complet
 ion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sargramostim#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07437963
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03126916-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Leukine (Sargramostim): Phase 3 readout est. (NCT03126916)
DESCRIPTION:Leukine (Sargramostim)\, phase 3.\nStudy: Testing the Addition 
 of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk N
 euroblastoma (NBL)\nEstimated primary completion: 30 September 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03126916
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06626516-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Leukine (Sargramostim): Phase 1/2 readout est. (NCT06626516)
DESCRIPTION:Leukine (Sargramostim)\, phase 1/2.\nStudy: Tebentafusp-tebn Wi
 th LDT in Metastatic UM\nEstimated primary completion: October 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06626516
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949760-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Leukine (Sargramostim): Phase 2 readout est. (NCT07949760)
DESCRIPTION:Leukine (Sargramostim)\, phase 2.\nStudy: WOKVAC Vaccine to Pre
 vent Brain Metastases in Metastatic HER2 Positive Breast Cancer\, SHIELD T
 rial\nEstimated primary completion: 31 December 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07949760
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05232916-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Leukine (Sargramostim): Phase 3 readout est. (NCT05232916)
DESCRIPTION:Leukine (Sargramostim)\, phase 3.\nStudy: Phase 3 Study to Eval
 uate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) i
 n HER2/Neu Positive Subjects\nEstimated primary completion: December 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sargramostim#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05232916
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02339571-6501@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Leukine (Sargramostim): Phase 2/3 readout est. (NCT02339571)
DESCRIPTION:Leukine (Sargramostim)\, phase 2/3.\nStudy: A Phase II/III Tria
 l of Nivolumab\, Ipilimumab\, and GM-CSF in Patients With Advanced Melanom
 a\nEstimated primary completion: 30 June 2033. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sargramostim#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT02339571
URL:https://assetmemo.bio/drug/sargramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
